Detrimental impact of immunosuppressive burden on clinical course in patients with Cytomegalovirus infection after liver transplantation.
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
revised:
14
10
2023
received:
07
12
2022
accepted:
06
11
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
Cytomegalovirus (CMV)-infection and reactivation remain a relevant complication after liver transplantation (LT). The recipient and donor serum CMV-IgG-status has been established for risk stratification when choosing various pharmaceutical regimens for CMV-prophylaxis in the last two decades. However, factors influencing course of CMV-infection in LT remain largely unknown. In this study, the impact of immunosuppressive regimen was examined in a large cohort of patients. All patients that underwent primary LT between 2006 and 2018 at the Charité-Universitaetsmedizin, Berlin, were included. Clinical course as well as histological and laboratory findings of patients were analyzed our prospectively maintained database. Univariate and multivariate regression analysis for impact of variables on CMV-occurrence was conducted, and survival was examined using Kaplan-Meier analysis. Overall, 867 patients were included in the final analysis. CMV-infection was diagnosed in 325 (37.5%) patients after transplantation. Significantly improved overall survival was observed in these patients (Log rank = 0.03). As shown by correlation and regression tree classification and regression tree analysis, the recipient/donor CMV-IgG-status with either positivity had the largest influence on CMV-occurrence. Analysis of immunosuppressive burden did not reveal statistical impact on CMV-infection, but statistically significant inverse correlation of cumulative tacrolimus trough levels and survival was found (Log rank < .001). Multivariate analysis confirmed these findings (p = .02). CMV-infection remains of clinical importance after LT. Undergone CMV-infection of either recipient or donor requires prophylactic treatment. Additionally, we found a highly significant, dosage-dependent impact of immunosuppression (IS) on long-term outcomes for these patients, underlying the importance of minimization of IS in liver transplant recipients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14196Informations de copyright
© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Mahmud N. Selection for liver transplantation: indications and evaluation. Curr Hepatol Rep. 2020;19:203-212. doi:10.1007/s11901-020-00527-9
Zanetto A, Shalaby S, Gambato M, et al. New indications for liver transplantation. J Clin Med. 2021;10:3867.
Di Maira T, Little EC, Berenguer M. Immunosuppression in liver transplant. Best Pract Res Clin Gastroenterol. 2020;46-47:101681. doi:10.1016/j.bpg.2020.101681
Cillo U, De Carlis L, Del Gaudio M, et al. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int. 2020;14:930-943. doi:10.1007/s12072-020-10091-5
Charlton M, Levitsky J, Aqel B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102:727-743. doi:10.1097/tp.0000000000002147
Lew J, Perito ER, Feng S. We asked the experts: toward personalized immunosuppression for liver transplant recipients. World J Surg. 2022;46:876-877. doi:10.1007/s00268-021-06417-5
Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. World J Hepatol. 2015;7:1355-1368. doi:10.4254/wjh.v7.i10.1355
Kaltenborn A, Schrem H. Mycophenolate mofetil in liver transplantation: a review. Ann Transplant. 2013;18:685-696. doi:10.12659/aot.889299
Spiritos Z, Abdelmalek MF. Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol. 2020;6:13.
Benvenuto LJ, Anderson MR, Arcasoy SM. New frontiers in immunosuppression. J Thorac Dis. 2018;10:3141-3155. doi:10.21037/jtd.2018.04.79
Halleck F, Friedersdorff F, Fuller TF, et al. New perspectives of immunosuppression. Transplant Proc. 2013;45:1224-1231. doi:10.1016/j.transproceed.2013.02.033
Bamoulid J, Staeck O, Halleck F, et al. The need for minimization strategies: current problems of immunosuppression. Transpl Int. 2015;28:891-900. doi:10.1111/tri.12553
Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant. 2014;19:253-260. doi:10.1097/mot.0000000000000069
Rodríguez-Perálvarez M, Colmenero J, González A, et al. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. Am J Transplant. 2022;22(6):1671-1682. doi:10.1111/ajt.17021
Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67:1167-1198. doi:10.2165/00003495-200767080-00006
Singh N, Limaye AP. Infections in solid-organ transplant recipients. In. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases; 2015:3440-3452. doi:10.1016/B978-1-4557-4801-3.00313-1. Epub 2014 Oct 31.
Romero FA, Razonable RR. Infections in liver transplant recipients. World J Hepatol. 2011;3:83-92. doi:10.4254/wjh.v3.i4.83
Hernandez Mdel P, Martin P, Simkins J. Infectious complications after liver transplantation. Gastroenterol Hepatol (NY). 2015;11:741-753.
Mohanraj BS, Rangnekar AS, Timpone JG. Infections in liver transplantation. In: Safdar A, ed. Principles and Practice of Transplant Infectious Diseases. Springer; 2019:41-72.
Weigand K, Schnitzler P, Schmidt J, et al. Cytomegalovirus infection after liver transplantation incidence, risks, and benefits of prophylaxis. Transplant Proc. 2010;42:2634-2641. doi:10.1016/j.transproceed.2010.04.025
Kanj SS, Sharara AI, Clavien P-A, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis. 1996;22:537-549. doi:10.1093/clinids/22.3.537
Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of Cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation. 2006;81:1645-1652. doi:10.1097/01.tp.0000226071.12562.1a
Lizaola-Mayo BC, Rodriguez EA. Cytomegalovirus infection after liver transplantation. World J Transplant. 2020;10:183-190. doi:10.5500/wjt.v10.i7.183
Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008;14:4849-4860. doi:10.3748/wjg.14.4849
Engelmann C, Sterneck M, Weiss KH, et al. Prevention and management of CMV infections after liver transplantation: current practice in German transplant centers. J Clin Med. 2020;9:2352. doi:10.3390/jcm9082352
Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother. 2013;45:260-271. doi:10.3947/ic.2013.45.3.260
Zarrinpar A, Lee DK, Silva A, et al. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. Sci Transl Med. 2016;8:333-349. doi:10.1126/scitranslmed.aac5954
Tasdogan BE, Ma M, Simsek C, Saberi B, Gurakar A. Update on immunosuppression in liver transplantation. Euroasian J Hepatogastroenterol. 2019;9:96-101. doi:10.5005/jp-journals-10018-1301
Tacke F, Kroy DC, Barreiros AP, Neumann UP. Liver transplantation in Germany. Liver Transpl. 2016;22:1136-1142. doi:10.1002/lt.24461
Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int. 2005;68:1834-1839. doi:10.1111/j.1523-1755.2005.00602.x
Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016;16:2816-2835. doi:10.1111/ajt.13909
Griffiths P, Reeves M. Pathogenesis of human Cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19:759-773. doi:10.1038/s41579-021-00582-z
Yadav SK, Saigal S, Choudhary NS, Saha S, Kumar N, Soin AS. Cytomegalovirus infection in liver transplant recipients: current approach to diagnosis and management. J Clin Exp Hepatol. 2017;7:144-151. doi:10.1016/j.jceh.2017.05.011
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13512. doi:10.1111/ctr.13512
Onor IO, Todd SB, Meredith E, et al. Evaluation of clinical outcomes of prophylactic versus preemptive Cytomegalovirus strategy in liver transplant recipients. Transpl Int. 2013;26:592-600. doi:10.1111/tri.12101
Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R− kidney transplant recipients is associated with long-term reduction in Cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90:1427-1431. doi:10.1097/tp.0b013e3181ff1493
Kalil AC, Mindru C, Botha JF, et al. Risk of Cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl. 2012;18:1440-1447. doi:10.1002/lt.23530
Eid AJ, Razonable RR. Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities. Curr Opin Organ Transplant. 2007;12:610-617. doi:10.1097/MOT.0b013e3282f0d386
Khawaja F, Spallone A, Kotton CN, Chemaly RF. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. Clin Microbiol Infect. 2022;29(1):P44-P50. doi:10.1016/j.cmi.2022.07.001
Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of Cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102:900-931. doi:10.1097/tp.0000000000002191
Zimmerman RK, Balasubramani GK, Nowalk MP, et al. Classification and regression tree (CART) analysis to predict influenza in primary care patients. BMC Infect Dis. 2016;16:503. doi:10.1186/s12879-016-1839-x
Druschel C, Ossami Saidy RR, Grittner U, et al. Clinical decision-making on spinal cord injury-associated pneumonia: a nationwide survey in Germany. Spinal Cord. 2020;58:873-881. doi:10.1038/s41393-020-0435-5
Lemon SC, Roy J, Clark MA, Friedmann PD, Rakowski W. Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med. 2003;26:172-181. doi:10.1207/s15324796abm2603_02
Issa NC, Fishman JA, Snydman DR. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48:772-786. doi:10.1086/597089
Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant. 2008;22:200-210. doi:10.1111/j.1399-0012.2007.00774.x
Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation. 2001;72:1050-1055. doi:10.1097/00007890-200109270-00012
Bittermann T, Hubbard RA, Lewis JD, Goldberg DS. The use of induction therapy in liver transplantation is highly variable and is associated with posttransplant outcomes. Am J Transplant. 2019;19:3319-3327. doi:10.1111/ajt.15513
Turner AP, Knechtle SJ. Induction immunosuppression in liver transplantation: a review. Transpl Int. 2013;26:673-683. doi:10.1111/tri.12100
Toupance O, Bouedjoro-Camus MC, Carquin J, et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transpl Int. 2000;13:413-419. doi:10.1007/s001470050723
Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):93-106. doi:10.1111/ajt.12103
Erdbruegger U, Scheffner I, Mengel M, et al. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant. 2012;27:435-443. doi:10.1093/ndt/gfr306
Evans PC, Soin A, Wreghitt TG, Taylor CJ, Wight DG, Alexander GJ. An association between Cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation. 2000;69:30-35. doi:10.1097/00007890-200001150-00007
Levitsky J, Goldberg D, Smith AR, et al. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. Clin Gastroenterol Hepatol. 2017;15:584-593.e582. doi:10.1016/j.cgh.2016.07.035
Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. Acute and chronic rejection after liver transplantation: what a clinician needs to know. J Clin Exp Hepatol. 2017;7:358-366. doi:10.1016/j.jceh.2017.10.003
Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis. 2009;29:091-101.
Fisher LR, Henley KS, Lucey MR. Acute cellular rejection after liver transplantation: variability, morbidity, and mortality. Liver Transpl Surg. 1995;1:10-15. doi:10.1002/lt.500010104
Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg. 1999;5:S107-114. doi:10.1053/JTLS005s00107
Gül-Klein S, Kästner A, Haber PK, et al. Recurrence of hepatocellular carcinoma after liver transplantation is associated with episodes of acute rejections. J Hepatocell Carcinoma. 2021;8:133-143. doi:10.2147/jhc.S292010
Taner T. Liver transplantation: rejection and tolerance. Liver Transpl. 2017;23:S85-S88. doi:10.1002/lt.24840
Jamalidoust M, Namayandeh M, Pouladfar G, Ziyaeyan M. Post-liver transplant Cytomegalovirus (CMV) reactivation, graft, and patient survival rates in Iranian population. Jundishapur J Microbiol. 2021;14:e112775. doi:10.5812/jjm.112775
Kim JM, Kim SJ, Joh JW, et al. Is Cytomegalovirus infection dangerous in Cytomegalovirus-seropositive recipients after liver transplantation? Liver Transpl. 2011;17:446-455. doi:10.1002/lt.22249
Wojciechowski D, Wiseman A. Long-term immunosuppression management: opportunities and uncertainties. Clin J Am Soc Nephrol. 2021;16:1264-1271. doi:10.2215/cjn.15040920
Nguyen LS, Vautier M, Allenbach Y, et al. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf. 2019;42:813-825. doi:10.1007/s40264-019-00810-9
Gül-Klein S, Schmitz P, Schöning W, et al. The role of immunosuppression for recurrent cholangiocellular carcinoma after liver transplantation. Cancers (Basel). 2022;14:2890. doi:10.3390/cancers14122890
Ossami Saidy RR, Postel MP, Pflüger MJ, et al. Minimization of immunosuppressive therapy is associated with improved survival of liver transplant patients with recurrent hepatocellular carcinoma. Cancers (Basel). 2021;13:1617. doi:10.3390/cancers13071617
Pesthy S, Wegener E, Ossami Saidy RR, et al. Reducing immunosuppression in patients with de novo lung carcinoma after liver transplantation could significantly prolong survival. Cancers (Basel). 2022;14:2748. doi:10.3390/cancers14112748
Toti L, Manzia TM, Blasi F, Tisone G. Withdrawal of immunosuppression after liver transplantation. In: Liver Transplantation. Wiley; 2021:386-392.
Shaked A, DesMarais MR, Kopetskie H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. Am J Transplant. 2019;19:1397-1409. doi:10.1111/ajt.15205
Tanimine N, Ohira M, Tahara H, et al. Strategies for deliberate induction of immune tolerance in liver transplantation: from preclinical models to clinical application. Front Immunol. 2020;11:1615. doi:10.3389/fimmu.2020.01615
Rodríguez-Perálvarez M, Rico-Juri JM, Tsochatzis E, Burra P, De la Mata M, Lerut J. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. Transpl Int. 2016;29:961-973. doi:10.1111/tri.12737
Gruttadauria S, Vasta F, Mandalà L, et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc. 2005;37:2611-2613. doi:10.1016/j.transproceed.2005.06.063
Maluf DG, Stravitz RT, Cotterell AH, et al. Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant. 2005;5:149-156. doi:10.1111/j.1600-6143.2004.00654.x
Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638-645. doi:10.1002/hep.510280306
Wolf S, Lauseker M, Schiergens T, et al. Infections after kidney transplantation: a comparison of mTOR-Is and CNIs as basic immunosuppressants. A systematic review and meta-analysis. Transpl Infect Dis. 2020;22:e13267. doi:10.1111/tid.13267
Ghazal K, Stenard F, Dahlqvist G, et al. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity. Clin Res Hepatol Gastroenterol. 2018;42:237-244. doi:10.1016/j.clinre.2017.10.001